Semaglutide for osteoarthritis: Difference between revisions
Created page with "A study published in the ''New England Journal of Medicine'' on October 31st highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain rela..." |
No edit summary |
||
| Line 1: | Line 1: | ||
A study published in the ''New England Journal of Medicine'' on October 31st highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain related to knee osteoarthritis in individuals with obesity, as compared to a placebo. | [[File:Areas affected by osteoarthritis.gif|Areas affected by osteoarthritis|thumb|left]] | ||
A [https://www.nejm.org/doi/full/10.1056/NEJMoa2403664 study] published in the ''New England Journal of Medicine'' on October 31st highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain related to knee osteoarthritis in individuals with obesity, as compared to a placebo. | |||
=== Study Overview === | === Study Overview === | ||
[[File:Ozempic® 3ml.jpg|Ozempic|thumb|right]] | |||
The study, led by Henning Bliddal, M.D., from Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, involved a 68-week trial conducted at 61 sites across 11 countries. A total of 407 participants with obesity and clinically confirmed moderate knee osteoarthritis, characterized by moderate to severe pain, were enrolled in the study. Participants were randomly assigned in a 2:1 ratio to receive either once-weekly subcutaneous semaglutide or a placebo, in addition to counseling on physical activity and a reduced-calorie diet. | The study, led by Henning Bliddal, M.D., from Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, involved a 68-week trial conducted at 61 sites across 11 countries. A total of 407 participants with obesity and clinically confirmed moderate knee osteoarthritis, characterized by moderate to severe pain, were enrolled in the study. Participants were randomly assigned in a 2:1 ratio to receive either once-weekly subcutaneous semaglutide or a placebo, in addition to counseling on physical activity and a reduced-calorie diet. | ||
Revision as of 03:13, 1 November 2024
A study published in the New England Journal of Medicine on October 31st highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain related to knee osteoarthritis in individuals with obesity, as compared to a placebo.
Study Overview
The study, led by Henning Bliddal, M.D., from Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, involved a 68-week trial conducted at 61 sites across 11 countries. A total of 407 participants with obesity and clinically confirmed moderate knee osteoarthritis, characterized by moderate to severe pain, were enrolled in the study. Participants were randomly assigned in a 2:1 ratio to receive either once-weekly subcutaneous semaglutide or a placebo, in addition to counseling on physical activity and a reduced-calorie diet.
Key Findings
The results demonstrated that:
- Body Weight Reduction: By week 68, participants receiving semaglutide experienced a mean body weight reduction of −13.7%, compared to −3.2% in the placebo group.
- Pain Reduction: The mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score was −41.7 points for the semaglutide group and −27.5 points for the placebo group.
- Improvement in Physical Function: The 36-Item Short Form Health Survey showed greater improvement in physical function among the semaglutide group, with a mean increase of 12.0 points compared to 6.5 points in the placebo group.
The incidence of serious adverse events was similar between the two groups, indicating that semaglutide was well-tolerated by participants.
